Virosome-formulated Plasmodium falciparum AMA-1 & CSP derived peptides as malaria vaccine: randomized phase 1b trial in semi-immune adults & children.
This trial was conducted to evaluate the safety and immunogenicity of two virosome formulated malaria peptidomimetics derived from Plasmodium falciparum AMA-1 and CSP in malaria semi-immune adults and children.The design was a prospective randomized, double-blind, controlled, age-deescalating study...
Main Authors: | Patrick Georges Cech, Thomas Aebi, Mwanajaa Shomari Abdallah, Maxmillian Mpina, Ester Barnabas Machunda, Nicole Westerfeld, Sabine Alexandra Stoffel, Rinaldo Zurbriggen, Gerd Pluschke, Marcel Tanner, Claudia Daubenberger, Blaise Genton, Salim Abdulla |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2011-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3142124?pdf=render |
Similar Items
-
Immunogenicity of a virosomally-formulated <it>Plasmodium falciparum </it>GLURP-MSP3 chimeric protein-based malaria vaccine candidate in comparison to adjuvanted formulations
by: Tamborrini Marco, et al.
Published: (2011-12-01) -
A randomized placebo-controlled phase Ia malaria vaccine trial of two virosome-formulated synthetic peptides in healthy adult volunteers.
by: Blaise Genton, et al.
Published: (2007-10-01) -
A virosomal malaria peptide vaccine elicits a long-lasting sporozoite-inhibitory antibody response in a phase 1a clinical trial.
by: Shinji L Okitsu, et al.
Published: (2007-12-01) -
Evidence of blood stage efficacy with a virosomal malaria vaccine in a phase IIa clinical trial.
by: Fiona M Thompson, et al.
Published: (2008-01-01) -
Correction: Evidence of Blood Stage Efficacy with a Virosomal Malaria Vaccine in a Phase IIa Clinical Trial.
by: Fiona M. Thompson, et al.
Published: (2011-01-01)